Europe’s first dual orexin receptor antagonist – QUVIVIQTM (daridorexant) – granted approval
QUVIVIQTM (daridorexant) is now available in the US for adults
living with insomnia
PIVLAZTM (clazosentan) – Idorsia’s
first commercial product – now
available for patients in Japan
Results of the
2022 Annual General
Meeting of Shareholders
Daridorexant Phase 3
data published in
The Lancet Neurology
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Idorsia’s success depends on its people.
Idorsia's development compounds target a number of different diseases.
| 26 Jul 2022 | |
| 23 May 2022 | |
| 10 May 2022 |
| Event | When |
|
Nine-months 2022 Financial Results reporting* |
October 25, 2022
|
|
Full-Year 2022 Financial Results reporting* |
February 7, 2023
|
|
First Quarter 2023 Financial Results reporting* |
April 25, 2023
|
*We will be in a silent period for 10 days ahead of the financial reporting.
